medical sciences |
32 |
chronic hepatitis b |
28 |
gastroenterology |
26 |
hepatocellular carcinoma |
24 |
nafld |
24 |
cirrhosis |
23 |
hbv |
22 |
adult |
20 |
hepatitis b |
20 |
hepatitis b surface antigen |
19 |
entecavir |
18 |
hepatitis b virus |
18 |
liver fibrosis |
18 |
liver transplantation |
18 |
nucleoside analogues |
18 |
antiviral therapy |
17 |
humans |
17 |
aged |
16 |
female |
16 |
liver stiffness |
16 |
male |
16 |
middle aged |
16 |
hbsag |
15 |
cap |
14 |
colonoscopy |
14 |
functional cure |
14 |
prognosis |
14 |
tenofovir |
14 |
liver biopsy |
13 |
metabolic syndrome |
13 |
vcte |
13 |
antiviral |
12 |
fibrosis |
12 |
seroclearance |
12 |
vaccination |
12 |
acute flare |
11 |
anti-hbs |
11 |
biomarkers |
11 |
body mass index |
11 |
chronic liver disease |
11 |
controlled attenuation parameter |
11 |
decompensation |
11 |
hepatitis b core-related antigen |
11 |
hepatitis c |
11 |
liver failure |
11 |
long covid |
11 |
meld |
11 |
non-alcoholic fatty liver disease |
11 |
post-covid-19 syndrome |
11 |
sars-cov-2 infection |
11 |
virus replication |
11 |
adolescent |
10 |
aged, 80 and over |
10 |
biomarker |
10 |
hbcrag |
10 |
hbv dna |
10 |
hcc |
10 |
m2bpgi |
10 |
surface antigen |
10 |
adefovir |
9 |
alanine transaminase - blood |
9 |
elasticity imaging techniques |
9 |
epidemiology |
9 |
fatty liver disease |
9 |
flare |
9 |
hav |
9 |
hbeag |
9 |
hcv |
9 |
hev |
9 |
immigration |
9 |
lamivudine |
9 |
mutation |
9 |
nash |
9 |
natural history |
9 |
non-viral liver disease |
9 |
nucleoside analogue |
9 |
pre-s deletions |
9 |
tumorigenesis |
9 |
carrier state |
8 |
core protein allosteric modulator |
8 |
elasticity imaging techniques - methods |
8 |
endocrinology |
8 |
fatty liver |
8 |
hepatitis b core antigen |
8 |
hepatitis b, chronic - complications - diagnosis |
8 |
hepatitis b, chronic - pathology |
8 |
hepatitis c virus |
8 |
hla‐dp |
8 |
ifn‐γ pathway |
8 |
liver cirrhosis - complications - diagnosis |
8 |
liver cirrhosis - pathology - virology |
8 |
liver failure - pathology - virology |
8 |
models, biological |
8 |
mortality |
8 |
nephrotoxicity |
8 |
nucleos(t)ide analogue |
8 |
predictive value of tests |
8 |
reproducibility of results |
8 |
serology |
8 |
telbivudine |
8 |
transplantation |
8 |
tricuspid annuloplasty |
8 |
accuracy |
7 |
adenocarcinoma |
7 |
advanced cirrhosis |
7 |
alanine aminotransferase blood level |
7 |
alanine transaminase - metabolism |
7 |
alkaline phosphatase |
7 |
biliary |
7 |
carcinoma, hepatocellular - etiology |
7 |
carcinoma, hepatocellular - virology |
7 |
cholangiogram |
7 |
chronic viral hepatitis |
7 |
colon cancer |
7 |
colorectal cancer |
7 |
covalently closed circular dna |
7 |
covid-19 |
7 |
diabetes mellitus |
7 |
diagnostic test accuracy study |
7 |
disease progression |
7 |
disease severity |
7 |
dna, viral - analysis |
7 |
drug response |
7 |
elastography |
7 |
etv |
7 |
gastric cancer |
7 |
gastroenterology medical sciences |
7 |
hepatitis b e antigens - metabolism |
7 |
hepatitis b virus - physiology |
7 |
hepatitis b virus infection |
7 |
hepatitis b, chronic - complications |
7 |
hepatitis b, chronic - drug therapy - virology |
7 |
hepatitis b, chronic - enzymology - pathology |
7 |
hepatorenal syndrome |
7 |
interval cancer |
7 |
itraq |
7 |
ketamine |
7 |
liver cirrhosis - enzymology - pathology |
7 |
liver cirrhosis - etiology |
7 |
liver neoplasms - virology |
7 |
mafld |
7 |
magnetic resonance cholangiography |
7 |
metabolic |
7 |
obesity |
7 |
substance abuse |
7 |
surgery |
7 |
treatment outcome |
7 |
vaccine |
7 |
adverse outcome |
6 |
age |
6 |
alanine aminotransferase |
6 |
anti-bacterial agents - pharmacology |
6 |
anti-hbc |
6 |
antibody to hepatitis b surface antigen |
6 |
aspartate aminotransferase |
6 |
blood donors - statistics and numerical data |
6 |
carrier state - epidemiology - pathology |
6 |
cccdna |
6 |
circular dna |
6 |
clarithromycin |
6 |
colon neoplasms |
6 |
curative colectomy |
6 |
cure |
6 |
drug resistance, viral |
6 |
fibroscan |
6 |
follow up |
6 |
full-length genome sequencing |
6 |
genotype 1 |
6 |
genotype 6 |
6 |
gitr |
6 |
gram-positive bacterial infections - epidemiology - microbiology - mortality - physiopathology |
6 |
guanine - analogs and derivatives - therapeutic use |
6 |
helicobacter pylori |
6 |
hepacivirus - classification - genetics - pathogenicity |
6 |
hepaticolenticular degeneration |
6 |
hepatitis b core‐related antigen |
6 |
hepatitis b e antigens - blood |
6 |
hepatitis b serum markers |
6 |
hepatitis b virus - drug effects |
6 |
hepatitis b(e) antigen |
6 |
hepatitis b, chronic - blood - drug therapy - virology |
6 |
hepatitis b, chronic - complications - drug therapy |
6 |
hepatitis b, chronic - epidemiology - pathology |
6 |
hepatitis c, chronic - complications - metabolism - virology |
6 |
hong kong - epidemiology |
6 |
host-pathogen interactions |
6 |
hs-hbsag |
6 |
interleukin‐27 |
6 |
intrahepatic hbv dna |
6 |
kinetics |
6 |
lamivudine - adverse effects - therapeutic use |
6 |
lamivudine - pharmacology - therapeutic use |
6 |
levofloxacin |
6 |
liver - pathology |
6 |
liver neoplasms - etiology |
6 |
longitudinal |
6 |
mac-2 binding protein glycosylation isomer |
6 |
microbial sensitivity tests |
6 |
na therapy |
6 |
nucleotide analogue |
6 |
pd-1 |
6 |
platelet ratio index |
6 |
primary biliary cholangitis |
6 |
prospective studies |
6 |
quasispecies |
6 |
recurrence |
6 |
regulatory t cells |
6 |
response to therapy |
6 |
retrospective studies |
6 |
reverse transcriptase inhibitors - therapeutic use |
6 |
risk factors |
6 |
shewanella - classification - drug effects - isolation & purification - pathogenicity |
6 |
spontaneous hbeag seroconversion |
6 |
tenofovir hbsag surface antigen nucleoside analogue nucleotide analogue tdf |
6 |
time factors |
6 |
transient elastography |
6 |
ursodeoxycholic acid |
6 |
viral hepatitis |
6 |
virus dna |
6 |
wfa + -m2bp |
6 |
anaemia |
5 |
angiotensin-converting enzyme inhibitors |
5 |
antiviral agents - administration and dosage - therapeutic use |
5 |
antiviral agents - adverse effects - therapeutic use |
5 |
biliary tract diseases - chemically induced - diagnosis |
5 |
cancer incidence |
5 |
cancer risk |
5 |
carcinoma, hepatocellular - diagnosis - pathology |
5 |
carcinoma, hepatocellular - epidemiology - genetics - virology |
5 |
ceruloplasmin - metabolism |
5 |
china |
5 |
cholangiopancreatography, endoscopic retrograde |
5 |
cohort analysis |
5 |
colonic neoplasms |
5 |
comorbidity |
5 |
copper/urine |
5 |
core antigen |
5 |
core protein |
5 |
customized therapies |
5 |
deep sequencing |
5 |
deleterious mutations |
5 |
dna mutational analysis - methods |
5 |
dna, viral - blood |
5 |
dyslipidemia |
5 |
efficacy |
5 |
freezing |
5 |
gene deletion |
5 |
gene silencing |
5 |
genotype |
5 |
guanine - administration and dosage - analogs and derivatives - therapeutic use |
5 |
hbeag seroconversion |
5 |
hbsag seroclearance |
5 |
hbv // chb |
5 |
hbx protein |
5 |
hepatitis b e antigen |
5 |
hepatitis b surface antigens - blood |
5 |
hepatitis b surface antigens - blood - chemistry |
5 |
hepatitis b surface antigens - genetics |
5 |
hepatitis b virus - chemistry - classification - genetics |
5 |
hepatitis b virus - classification - genetics |
5 |
hepatitis b virus - drug effects - genetics |
5 |
hepatitis b virus - genetics |
5 |
hepatitis b virus - genetics - immunology - isolation and purification |
5 |
hepatitis b virus - genetics - isolation and purification |
5 |
hepatitis b virus dna rebound |
5 |
hepatitis b virus replication |
5 |
hepatitis b, chronic - complications - genetics - virology |
5 |
hepatitis b, chronic - complications - mortality - pathology |
5 |
hepatitis b, chronic - drug therapy - enzymology - immunology |
5 |
hepatitis b, chronic - epidemiology - physiopathology - virology |
5 |
hepatolenticular degeneration - complications - diagnosis - drug therapy - genetics - metabolism |
5 |
herbal medicine |
5 |
immune response |
5 |
immunomodulator |
5 |
inflammatory bowel disease |
5 |
inhalant abuse - complications |
5 |
intrahepatic hepatitis b virus dna |
5 |
ketamine - administration and dosage - adverse effects |
5 |
lamivudine - administration & dosage - therapeutic use |
5 |
linearized hbsag |
5 |
liver cancer |
5 |
liver histology |
5 |
liver neoplasms - epidemiology - genetics - virology |
5 |
liver steatosis |
5 |
medical sciences - oncology |
5 |
medical sciences - urology and nephrology |
5 |
nsaid |
5 |
nucleocapsid |
5 |
obese mice |
5 |
occult hepatitis b infection |
5 |
post‐colonoscopy colorectal cancer |
5 |
prevention |
5 |
propensity score |
5 |
protein precursors - genetics |
5 |
protein stability |
5 |
quantitative |
5 |
renin |
5 |
resistance |
5 |
reverse transcriptase inhibitors - administration & dosage - therapeutic use |
5 |
ribavirin |
5 |
risk assessment |
5 |
s-loss |
5 |
single polynucleotide polymorphisms |
5 |
specimen handling - methods |
5 |
statins |
5 |
steatosis |
5 |
stopping |
5 |
survival analysis |
5 |
sustained virologic response |
5 |
targeted sequencing |
5 |
therapeutic vaccine |
5 |
transcription |
5 |
translation |
5 |
treatment guidelines |
5 |
type 2 |
5 |
urologic diseases - chemically induced |
5 |
viraemia |
5 |
viral load |
5 |
virology |
5 |
young adult |
5 |
13c-urea breath test |
4 |
adjuvant |
4 |
adverse effects |
4 |
alt |
4 |
amoxicillin - therapeutic use |
4 |
anti-bacterial agents - therapeutic use |
4 |
anti-hepatitis b core total antibodies |
4 |
antibiotic resistance genes |
4 |
antibiotics |
4 |
antisense oligonucleotide |
4 |
antiviral treatment |
4 |
apoptosis |
4 |
artificial intelligence |
4 |
b cell depletion |
4 |
bacteroides |
4 |
bariatric surgery - mortality |
4 |
besifovir |
4 |
bile acid |
4 |
biliary atresia |
4 |
biocide resistance genes |
4 |
breast feeding |
4 |
cancer |
4 |
capsid inhibitor |
4 |
carnitine |
4 |
carvedilol |
4 |
case report |
4 |
chinese |
4 |
chronic hepatitis b virus |
4 |
chronic kidney disease |
4 |
clarithromycin - therapeutic use |
4 |
colonic adenoma. |
4 |
colonic polyp |
4 |
cpsh |
4 |
cytokines |
4 |
diabetes mellitus, type 2 - prevention & control |
4 |
dialysis |
4 |
direct acting antiviral |
4 |
dna methylation |
4 |
dna polymerase inhibitor |
4 |
drug interaction |
4 |
drug therapy, combination - methods |
4 |
empirical first-line eradication |
4 |
end stage renal disease |
4 |
endocuff |
4 |
entry inhibitor |
4 |
estrogen |
4 |
face mask |
4 |
fanconi syndrome |
4 |
fatty liver - surgery |
4 |
finite |
4 |
gastric balloon |
4 |
gastric bypass - statistics & numerical data |
4 |
gastroplasty - statistics & numerical data |
4 |
gender difference |
4 |
genome editing |
4 |
global elimination |
4 |
gut microbiome |
4 |
hand sanitizer |
4 |
hbsag level |
4 |
hbv reactivation |
4 |
hbv rna |
4 |
hbv transcription |
4 |
helicobacter infections - drug therapy |
4 |
helicobacter pylori - drug effects |
4 |
helicobacter pylori - treatment |
4 |
hepatitis |
4 |
hepatitis b core protein |
4 |
hepatitis b e antigen (hbeag) |
4 |
hepatitis b virus (hbv) dna |
4 |
hepatitis b virus rna |
4 |
histone acetylation |
4 |
hong kong |
4 |
hq-hbsag |
4 |
hsct |
4 |
ibrutinib |
4 |
ici |
4 |
inflammation |
4 |
integrated dna |
4 |
interleukin-1 receptor type 1 knockout mice |
4 |
interleukin-1β |
4 |
ip-10 |
4 |
kidney |
4 |
kidney failure, chronic - therapy |
4 |
kidney transplantation |
4 |
lactic acidosis |
4 |
liver |
4 |
liver and renal dysfunction |
4 |
liver transient elastography |
4 |
liver transplant |
4 |
long-term |
4 |
malnutrition - etiology |
4 |
microbiota |
4 |
microrna |
4 |
model for end-stage liver disease |
4 |
muscle toxicity |
4 |
myopathy |
4 |
nadolol |
4 |
neoadjuvant |
4 |
noninvasive |
4 |
novel therapy |
4 |
nsbb |
4 |
nucleos(t)ide analogs |
4 |
nucleoside analog |
4 |
nucleoside/ nucleotide analogue |
4 |
nucleotide analog |
4 |
obesity - surgery |
4 |
occult hepatitis b |
4 |
ofloxacin - therapeutic use |
4 |
omeprazole - therapeutic use |
4 |
oral therapy |
4 |
osteomalacia |
4 |
outcome |
4 |
peripheral neuropathy |
4 |
peritoneal dialysis |
4 |
peritonitis |
4 |
pharmacokinetics |
4 |
polymerase inhibitor |
4 |
portal hypertension |
4 |
prevalence |
4 |
programmed cell death protein 1 |
4 |
propranolol |
4 |
protease inhibitor |
4 |
real-life |
4 |
renal dialysis - adverse effects |
4 |
renal toxicity |
4 |
rituximab |
4 |
rna interfering gene silencer |
4 |
rnai |
4 |
safety |
4 |
sars-cov-2 |
4 |
superior mesenteric artery syndrome |
4 |
superior mesenteric artery syndrome - etiology - radiography - therapy |
4 |
systemic therapy |
4 |
teratogenecity |
4 |
thiopurine |
4 |
tki |
4 |
tlr7 agonist |
4 |
tricuspid regurgitation |
4 |
varices |
4 |
viral entry inhibitor |
4 |
viremia |
4 |
weight loss - physiology |
4 |
acute-on-chronic liver failure |
3 |
adenosine a3 receptor |
3 |
adverse effect |
3 |
albendazole |
3 |
antiviral agents - therapeutic use |
3 |
arc-520 |
3 |
carcinoma |
3 |
chronic |
3 |
coronavac |
3 |
cost–utility analysis |
3 |
covid-19 vaccine |
3 |
cpams |
3 |
direct-acting antiviral agents |
3 |
elbasvir/grazoprevir |
3 |
end stage liver disease - etiology - therapy |
3 |
gut microbiota |
3 |
healthcare dataset |
3 |
hepacivirus - genetics |
3 |
hepatitis b virus dna |
3 |
hepatitis b, chronic - complications - virology |
3 |
hepatitis c virus (hcv) |
3 |
hepatitis c, chronic - drug therapy - genetics - virology |
3 |
hepato-cellular carcinoma |
3 |
hepatocellular |
3 |
immunocompromised |
3 |
immunomodulation |
3 |
incidence |
3 |
interferon-alfa |
3 |
interleukins - genetics - therapeutic use |
3 |
linkage-to-care |
3 |
liver failure, acute - etiology - therapy |
3 |
liver neoplasms |
3 |
model of end-stage liver disease |
3 |
monitor |
3 |
myrcludex b |
3 |
nucleocapsids |
3 |
pancytopenia |
3 |
polymorphism, single nucleotide |
3 |
primary care |
3 |
rectal cancer |
3 |
strongyloidiasis |
3 |
subviral particles |
3 |
survival |
3 |
testing |
3 |
treatment |
3 |
treatment cessation |
3 |
ulcerative colitis |
3 |
vaccine immunogenicity |
3 |
2-cl-ib-meca |
2 |
asian |
2 |
atherosclerosis |
2 |
big data analytics |
2 |
big data management |
2 |
cardiovascular disease |
2 |
fg-3019 |
2 |
genotypes |
2 |
hbsag loss |
2 |
helipsav |
2 |
infectious disease |
2 |
infectious disease surveillance |
2 |
interferon-λ |
2 |
liver imaging |
2 |
machine learning |
2 |
msrc |
2 |
nf-kappa b |
2 |
nonalcoholic fatty liver disease |
2 |
nonalcoholic steatohepatitis |
2 |
proportional hazards models |
2 |
qnr family |
2 |
radiology |
2 |
rep 9ac |
2 |
rheumatoid arthritis (ra) |
2 |
roc curve |
2 |
scale-b |
2 |
sustained response |
2 |
tenofovir alafenamide |
2 |
tenofovir disoproxil fumarate |
2 |
5-羟色胺 |
1 |
5-羟色胺再摄取转运蛋白 |
1 |
alcohol |
1 |
antibody to hepatitis b core antigen |
1 |
antibody to tumor necrosis factor |
1 |
antigen cd20 |
1 |
body-mass index |
1 |
bone mineral density |
1 |
bone safety |
1 |
cardiovascular disease risk |
1 |
chronic hepatitis b virus infection |
1 |
coffee |
1 |
diabetes |
1 |
framingham risk score |
1 |
hbx基因 |
1 |
hematopoietic stem cell transplantation |
1 |
intestinal epithelial cells |
1 |
ldl |
1 |
non‐alcoholic steatohepatitis |
1 |
nuclear factor-κb |
1 |
occult |
1 |
physical activity |
1 |
renal safety |
1 |
thbxδ35 |
1 |
viremia reduction |
1 |
依从性 |
1 |
受试者 |
1 |
多西环素/治疗应用 |
1 |
影响因素 |
1 |
慢病毒载体 |
1 |
溃疡性结肠炎 |
1 |
细胞增殖 |
1 |
肝细胞 |
1 |
肠嗜铬细胞 |
1 |
色氨酸羟化酶1 |
1 |
药物临床试验 |
1 |
螺杆菌,幽门/药物作用 |
1 |
螺杆菌感染/药物疗法 |
1 |